SCHEMBL1339292

SCHEMBL1339292

Cn1c(=O)c(-c2ccc(Br)cc2)cc2c3cc(C(=O)CC(=O)COC4CCCCO4)ccc3n(C)c21

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.34
▸ GAA P10253 3/20 0.34
▸ HSD17B10 Q99714 3/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ KDM4E B2RXH2 4/20 0.33
▸ GLA P06280 2/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ HPGD P15428 2/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ EP300 Q09472 1/20 0.32
▸ CREBBP Q92793 1/20 0.32
▸ MAPK14 Q16539 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ PPARG P37231 1/20 0.31
▸ RAB9A P51151 1/20 0.30
▸ CNR2 P34972 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337155 0.85 DPP4 (0.34) KDM4EMAPK1LMNAPDE4BHPGD
SCHEMBL1338855 0.78 — —
SCHEMBL3258079 0.77 ALDH1A1 (0.33) ALDH1A1GAAHSD17B10SMN1; SMN2KDM4E
SCHEMBL1338964 0.76 GSK3B (0.41) GAAKDM4EMEN1KMT2APPARG
SCHEMBL1336807 0.74 ALDH1A1 (0.40) ALDH1A1GAASMN1; SMN2KDM4EMAPK1
SCHEMBL1338146 0.73 MEN1 (0.39) ALDH1A1GAAHSD17B10SMN1; SMN2KDM4E
SCHEMBL1338594 0.73 ASAH1 (0.34) ALDH1A1GAAKDM4EKMT2AMAPT
SCHEMBL3135467 0.72 KMT2A (0.39) ALDH1A1GAAHSD17B10SMN1; SMN2KDM4E
SCHEMBL3135471 0.70 KMT2A (0.36) ALDH1A1GAAHSD17B10SMN1; SMN2KDM4E
SCHEMBL1339068 0.69 MEN1 (0.36) ALDH1A1GAAHSD17B10SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 ALDH1A1 283/4885GAA 1532/4885HSD17B10 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback